Plas-free
Nes Ziona, Israel· Est.
Affinity‑based plasma filters for rapid removal of plasminogen and ammonia to treat bleeding and hyperammonemia.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Affinity‑based plasma filters for rapid removal of plasminogen and ammonia to treat bleeding and hyperammonemia.
HemostasisLiver disease
Technology Platform
Affinity‑based plasma filtration using ligand‑bound resin to selectively adsorb target molecules (e.g., plasminogen, ammonia) from blood products.
Opportunities
Rapid, point‑of‑care plasma filtration addresses unmet needs in trauma bleeding and acute hepatic encephalopathy, opening pathways to European and U.S.
hospital markets.
Risk Factors
Regulatory clearance beyond CE‑Mark, reimbursement approval, and competition from established blood‑product and hemostasis technologies could delay commercial uptake.
Competitive Landscape
Competes with hemostasis devices (e.g., Cevera, Haemonetics) and pharmacologic agents (TXA, ammonia‑lowering drugs); differentiation lies in selective molecular adsorption and fast treatment timelines.